The objective was to describe the prevalence, types, and predictors of adverse events (AEs) in rheumatoid arthritis (RA) patients treated with infliximab and methotrexate in a daily clinical setting.0Journal ArticleMulticenter StudyResearch Support, Non-U.S. Gov'tREMITRACT study groupinfo:eu-repo/semantics/publishe

De Keyser, Filip

Delabaye, Isabelle

Devogelaer, Jean-Pierre

Dufour, Jean-Pol

Durez, Patrick

Houssiau, Frédéric

REMITRACT study group

Crossref

Ghent University Academic Bibliography

PubMed Central

DI-fusion

DIAL UCLouvain

English

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and metaanalysis of rare harmful effects in randomized controlled trials. JAMA

Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs.

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol

Efficacy of biologicals in the treatment of rheumatoid arthritis. a meta-analysis. Pharmacology

Einarson TR, Keystone EC: The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposureadjusted pooled analyses of serious adverse events. Ann Rheum Dis

Feltelius N: Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis

Finckh A: Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 2009, 11(Suppl 1):S1.

Infliximab (chimeric antitumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet

Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis

Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum

McInnes IB: Evidence that cytokines play a role in rheumatoid arthritis.

Methotrexate in rheumatoid arthritis. Pharmacol Rep

MM: Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum

Proudman SM: Early combination disease modifying antirheumatic drug treatment for rheumatoid arthritis.

RN: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Strusberg AM: Rate and causes of infliximab discontinuation in patients with rheumatoid arthritis in a private clinical practice.

The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum

The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum

74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis